The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. [electronic resource]
Producer: 20191220Description: 491-504 p. digitalISSN:- 2211-3436
- Apoptosis -- drug effects
- Carcinoma, Pancreatic Ductal -- drug therapy
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- ErbB Receptors -- antagonists & inhibitors
- Humans
- Models, Biological
- Neoplasm Invasiveness
- Pancreatic Neoplasms -- drug therapy
- Quinazolinones -- pharmacology
- Radiation Tolerance
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.